Form 4: X4 Pharmaceuticals CEO Paula Ragan Receives 2,250,000 Restricted Stock Units

Paula Ragan, CEO of X4 Pharmaceuticals, was granted 2,250,000 restricted stock units under the company's equity incentive plan.

Summary

• Paula Ragan, the President and CEO of X4 Pharmaceuticals, received a grant of 2,250,000 restricted stock units on February 12, 2025.
• These restricted stock units were granted under the Issuer's Amended and Restated 2017 Equity Incentive Plan.
• Each restricted stock unit represents the right to receive one share of common stock on the applicable vesting date.
• No payment was made upon the grant of these restricted stock units.
• The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027, and February 12, 2028.
• Vesting is contingent upon Ms. Ragan's continued employment with X4 Pharmaceuticals through each vesting date.
• Following the transaction, Ms. Ragan beneficially owns 3,337,386 shares of common stock.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock grant. However, the grant suggests confidence in the CEO and the company's future, leading to a slightly positive sentiment.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing her to drive long-term value creation.
• The vesting schedule encourages continued service and commitment from the CEO.

Risks

• The value of the restricted stock units is dependent on the future performance of X4 Pharmaceuticals' stock.
• If Ms. Ragan leaves the company before the vesting dates, she will forfeit the unvested restricted stock units.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's financial performance or future prospects, focusing instead on the details of the stock grant.

Industry Context

Stock grants to executives are a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical for a company of X4 Pharmaceuticals' size and stage of development.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, and equity-based compensation.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize restricted stock units as part of their executive compensation plans.
• The vesting schedules for these grants typically range from three to five years, similar to the vesting schedule for Ms. Ragan's grant.
• The size of the grant is relative to the size of the company and the executive's role.

Stakeholder Impact

• Shareholders may view the stock grant positively as it aligns management's interests with theirs.
• Employees may be motivated by the fact that the CEO is incentivized to improve the company's performance.
• The grant has no immediate impact on customers, suppliers, or creditors.

Key Dates